Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.

Memory and executive deficits are important cognitive markers of Alzheimer's disease (AD). Moreover, in the past decade, cerebrospinal fluid (CSF) biomarkers have been increasingly utilized in clinical practice. Both cognitive and CSF markers can be used to differentiate between AD patients and healthy seniors with high diagnostic accuracy. However, the extent to which performance on specific mnemonic or executive tasks enables reliable estimations of the concentrations of different CSF markers and their ratios remains unclear. To address the above issues, we examined the association between neuropsychological data and CSF biomarkers in 51 AD patients using hierarchical multiple regression analyses. In the first step of these analyses, age, education and sex were entered as predictors to control for possible confounding effects. In the second step, data from a neuropsychological test battery assessing episodic memory, semantic memory and executive functioning were included to determine whether these variables significantly increased (compared to step 1) the explained variance in Aβ42 concentration, p-tau concentration, t-tau concentration, Aβ42/t-tau ratio, and Aβ42/Aβ40 ratio. The different models explained 52% of the variance in Aβ42/t-tau ratio, 27% of the variance in Aβ42 concentration, and 28% of the variance in t-tau concentration. In particular, Aβ42/t-tau ratio was associated with verbal recognition and code shifting, with Aβ42 being related to verbal recognition and t-tau being related to code shifting. By contrast, the inclusion of neuropsychological data did not allow reliable estimations of Aβ42/Aβ40 ratio or p-tau concentration. Our results showed that strong associations exist between the cognitive key symptoms of AD and the concentrations and ratios of specific CSF markers. In addition, we revealed a specific combination of neuropsychological tests that may facilitate reliable estimations of CSF concentrations, thereby providing important diagnostic information for non-invasive early AD detection.

Guhra M ，Thomas C ，Boedeker S ，Kreisel S ，Driessen M ，Beblo T ，Ohrmann P ，Toepper M ... -  《-》

Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.

Reijs BLR ，Ramakers IHGB ，Köhler S ，Teunissen CE ，Koel-Simmelink M ，Nathan PJ ，Tsolaki M ，Wahlund LO ，Waldemar G ，Hausner L ，Vandenberghe R ，Johannsen P ，Blackwell A ，Vanderstichele H ，Verhey F ，Visser PJ ... -  《-》

Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.

Reijs BLR ，Ramakers IHGB ，Elias-Sonnenschein L ，Teunissen CE ，Koel-Simmelink M ，Tsolaki M ，Wahlund LO ，Waldemar G ，Hausner L ，Johannsen P ，Vanderstichele H ，Verhey F ，Devanand DP ，Visser PJ ... -  《-》

Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.

Sauvée M ，DidierLaurent G ，Latarche C ，Escanyé MC ，Olivier JL ，Malaplate-Armand C ... -  《-》

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G ，Brønnick K ，Aarsland D ，Blennow K ，Zetterberg H ，Ballard C ，Kurz MW ，Andreasson U ，Tysnes OB ，Larsen JP ，Mulugeta E ... -  《-》